Skip to search formSkip to main contentSkip to account menu

foretinib

Known as: N-(3-Fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

GSK 1363089
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionXL880

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Activated HGF-c-Met Axis in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a highly morbid disease. Recent developments including Food and Drug… 
Review
2017
Review
2017
Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3, Axl and proto-oncogene… 
2015
2015
Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
2014
2014
MET inhibitors start on road to recovery
High-profile failures imperilled emerging anticancer MET inhibitors, but trials guided by a new biomarker are beginning to… 
2013
2013
Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
2013
2013
Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Highly Cited
2013
Highly Cited
2013
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
The proto-oncogene MET is aberrantly activated via overexpression or mutation in numerous cancers, making it a prime anticancer… 
Highly Cited
2011
Highly Cited
2011
Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis
Purpose: Currently, there are no approved targeted therapies for the treatment of ovarian cancer, despite the fact that it is the… 
Highly Cited
2011
Highly Cited
2011
Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death. Although sorafenib has been shown to improve survival… 
Review
2010
Review
2010
Molecularly targeted therapy in hepatocellular carcinoma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)